Abstract
Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (n=126) and nonpomalidomide cohorts (n=174), respectively (p<0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p<0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7months for nonpomalidomide cohort (log-rank p <0.01). Conclusion: Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
